[HTML][HTML] Carbohydrate-based drugs launched during 2000− 2021
X Cao, X Du, H Jiao, Q An, R Chen, P Fang… - … Pharmaceutica Sinica B, 2022 - Elsevier
Carbohydrates are fundamental molecules involved in nearly all aspects of lives, such as
being involved in formating the genetic and energy materials, supporting the structure of …
being involved in formating the genetic and energy materials, supporting the structure of …
α-and β-Glucosidase inhibitors: chemical structure and biological activity
EB de Melo, A da Silveira Gomes, I Carvalho - Tetrahedron, 2006 - Elsevier
Glycoside trimming enzymes are crucially important in a broad range of metabolic pathways,
including glycoprotein and glycolipid processing and carbohydrate digestion in the intestinal …
including glycoprotein and glycolipid processing and carbohydrate digestion in the intestinal …
Building bridges: Biocatalytic C–C-bond formation toward multifunctional products
NG Schmidt, E Eger, W Kroutil - ACS catalysis, 2016 - ACS Publications
Carbon–carbon bond formation is the key reaction for organic synthesis to construct the
carbon framework of organic molecules. The review gives a selection of biocatalytic C–C …
carbon framework of organic molecules. The review gives a selection of biocatalytic C–C …
Glycosidase inhibition: assessing mimicry of the transition state
TM Gloster, GJ Davies - Organic & biomolecular chemistry, 2010 - pubs.rsc.org
Glycoside hydrolases, the enzymes responsible for hydrolysis of the glycosidic bond in di-,
oligo-and polysaccharides, and glycoconjugates, are ubiquitous in Nature and fundamental …
oligo-and polysaccharides, and glycoconjugates, are ubiquitous in Nature and fundamental …
Synthesis and conformational and biological aspects of carbasugars
Carbohydrate chemistry constitutes today a “multifaceted” discipline strongly connected with
organic, pharmaceutical, and medicinal chemistry. 1 Carbohydrates are important …
organic, pharmaceutical, and medicinal chemistry. 1 Carbohydrates are important …
Molecular Evolution of an Aminotransferase Based on Substrate–Enzyme Binding Energy Analysis for Efficient Valienamine Synthesis
L Cui, A Cui, Q Li, L Yang, H Liu, W Shao, Y Feng - ACS Catalysis, 2022 - ACS Publications
Valienamine is a valuable building block for active pharmaceuticals and agrochemicals
because of its aminocyclitol structure and glucosidase inhibitory activity. Straightforward …
because of its aminocyclitol structure and glucosidase inhibitory activity. Straightforward …
One-pot synthesis of dihydropyrimidiones catalyzed by strontium (II) triflate under solvent-free conditions
W Su, J Li, Z Zheng, Y Shen - Tetrahedron Letters, 2005 - Elsevier
A simple, efficient and practical procedure for the Biginelli reaction using strontium (II) triflate
[Sr (OTf) 2] as a novel catalyst is described under solvent-free conditions in high yields. The …
[Sr (OTf) 2] as a novel catalyst is described under solvent-free conditions in high yields. The …
Sulfonamide chalcone as a new class of α-glucosidase inhibitors
WD Seo, JH Kim, JE Kang, HW Ryu… - Bioorganic & medicinal …, 2005 - Elsevier
Chalcones 1–20, a new class of glycosidase inhibitors, were synthesized, and their
glycosidase inhibitory activities were investigated. Non-aminochalcones 1–12 had no …
glycosidase inhibitory activities were investigated. Non-aminochalcones 1–12 had no …
Novel pharmacological approaches to the treatment of type 2 diabetes
EJ Verspohl - Pharmacological reviews, 2012 - ASPET
The huge increase in type 2 diabetes is a burden worldwide. Many marketed compounds do
not address relevant aspects of the disease; they may already compensate for defects in …
not address relevant aspects of the disease; they may already compensate for defects in …
Voglibose (Basen®, AO-128), one of the most important α-glucosidase inhibitors
X Chen, Y Zheng, Y Shen - Current medicinal chemistry, 2006 - ingentaconnect.com
The number of people with diabetes is expected to rise from the current estimated 150
million to 220 million in 2010 and 300 million in 2025, and 90% is Type 2 diabetes or non …
million to 220 million in 2010 and 300 million in 2025, and 90% is Type 2 diabetes or non …